Source: Cardiology | Posted 1 hr ago
Cardiovascular Outcomes Trials in Form 2 Diabetes Mellitus; Kapoor K, George P, Miller M; Cardiology 135 (2), 108-126 (Jun 2016)
OBJECTIVES To check out the spectrum of modern Cardio outcomes trials (CVOTS) in Form 2 diabetes mellitus (T2DM), spanning the two the pre- and post-ACCORD eras.
METHODS We checked out a overall of 12 CVOTs and delineated the 2 eras in accordance along with the 2008 US Meals and Medicine Administration (FDA) mandate requiring completion of CVOTs prior the licensing of brand-new glucose-decreasing agents. The salient implications about macrovascular health problem complications were summarized.
RESULTS 5 trials in the pre-ACCORD and 7 in the post-ACCORD period were identified. Heterogeneous Outcomes pertaining to the extent of glycemic regulate associated along with perfect macrovascular health problem threat reduction, also as the safest pharmacologic indicates to do so, were observed.
CONCLUSIONS The post-ACCORD period is agent of a considerable transition in the landscape of CVOTs in T2DM, along with an focus about security of glucose-decreasing agents. Lately completed and recurring trials of dipeptidyl peptidase-4 inhibitors and sodium-sugar cotransporter 2 inhibitors will certainly go on to inform medical method about secure and efficient means to lower CV threat in T2DM.
